| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
|
Lancet
|
2010
|
5.59
|
|
2
|
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
|
Blood
|
2011
|
2.74
|
|
3
|
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
|
Blood
|
2005
|
2.06
|
|
4
|
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
|
J Clin Oncol
|
2007
|
1.94
|
|
5
|
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
|
J Clin Oncol
|
2013
|
1.79
|
|
6
|
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
|
Haematologica
|
2007
|
1.59
|
|
7
|
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
|
Haematologica
|
2004
|
1.38
|
|
8
|
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
|
J Clin Oncol
|
2011
|
1.32
|
|
9
|
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
|
World J Surg Oncol
|
2007
|
1.09
|
|
10
|
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
|
Eur J Haematol
|
2006
|
0.99
|
|
11
|
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
|
Blood
|
2006
|
0.98
|
|
12
|
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
|
Semin Thromb Hemost
|
2011
|
0.96
|
|
13
|
The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.
|
Clin Nucl Med
|
2013
|
0.94
|
|
14
|
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
|
Biol Blood Marrow Transplant
|
2010
|
0.91
|
|
15
|
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
|
Eur J Haematol
|
2005
|
0.91
|
|
16
|
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.
|
Oncotarget
|
2014
|
0.90
|
|
17
|
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
|
Ann Hematol
|
2013
|
0.90
|
|
18
|
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
|
Eur J Haematol
|
2004
|
0.85
|
|
19
|
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
|
J Clin Oncol
|
2009
|
0.85
|
|
20
|
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
|
J Clin Oncol
|
2006
|
0.83
|
|
21
|
Thalidomide maintenance in multiple myeloma: certainties and controversies.
|
J Clin Oncol
|
2009
|
0.82
|
|
22
|
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
|
Eur J Haematol
|
2010
|
0.79
|
|
23
|
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
|
Ann Hematol
|
2011
|
0.77
|
|
24
|
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
|
Ann Hematol
|
2013
|
0.76
|
|
25
|
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.
|
Expert Rev Anticancer Ther
|
2014
|
0.76
|
|
26
|
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
|
Cutan Ocul Toxicol
|
2013
|
0.76
|
|
27
|
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
|
Eur J Haematol
|
2007
|
0.75
|
|
28
|
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
|
Ann Hematol
|
2006
|
0.75
|